As individuals advance in years, the integrity of the blood-brain barrier, a critical vascular structure responsible for shielding the brain from circulating toxins, tends to diminish. This normally impermeable membrane, composed of tightly knit blood vessels, acts as a vigilant guardian, preventing harmful substances present in the bloodstream from infiltrating delicate brain tissue. However, with the passage of time, this barrier can become compromised, exhibiting increased permeability and allowing the ingress of deleterious compounds. Such an influx is a significant contributor to neuroinflammation, a condition widely recognized for its association with cognitive decline and a hallmark of neurodegenerative disorders like Alzheimer’s disease.
A pivotal discovery made by the UCSF research team several years prior involved observing an elevated production of an enzyme, designated GPLD1, within the livers of mice that had undergone exercise regimens. This enzyme appeared to possess rejuvenating properties for the brain, yet a significant enigma persisted: GPLD1 itself lacks the capacity to traverse the blood-brain barrier. This inherent limitation left the scientific community perplexed as to the precise mechanism by which this enzyme could impart its cognitive benefits.
The recent investigation has now provided a definitive answer to this long-standing question. The scientists meticulously detailed how GPLD1 exerts its influence by interacting with another protein, known as TNAP. In aging mice, TNAP exhibits a tendency to accumulate within the cellular components that constitute the blood-brain barrier. This accumulation is directly implicated in the weakening of the barrier and the exacerbation of its leakiness. Conversely, when these mice engage in physical activity, their livers commence the release of GPLD1 into the systemic circulation. This circulating enzyme then navigates to the network of blood vessels surrounding the brain. Upon reaching its destination, GPLD1 effectively cleaves TNAP from the surface of the barrier’s constituent cells, thereby playing a crucial role in restoring and reinforcing the barrier’s structural integrity.
"This revelation underscores the profound interconnectedness between systemic bodily functions and the intricate processes of brain aging," stated Saul Villeda, PhD, an associate director at the UCSF Bakar Aging Research Institute. Dr. Villeda served as the senior author of the research paper, which was formally published in the esteemed journal Cell on February 18th.
In their pursuit to precisely delineate how GPLD1 orchestrates its effects, the research team concentrated on the enzyme’s inherent functional capability. GPLD1 is characterized by its ability to enzymatically sever specific protein molecules from cellular surfaces. Consequently, the researchers embarked on a systematic search for tissues that might harbor proteins susceptible to this enzymatic action, with a particular hypothesis that certain proteins might accumulate with advancing age.
The cells forming the blood-brain barrier emerged as particularly compelling subjects of investigation, as they were found to express several potential targets for GPLD1. Through rigorous laboratory experimentation, the scientists definitively identified that only one of these candidate proteins was effectively trimmed by GPLD1: TNAP.
Subsequent, more in-depth experiments served to conclusively affirm the pivotal role of TNAP in the progression of cognitive decline. The researchers engineered young mice to overproduce TNAP within their blood-brain barrier cells. These genetically modified animals subsequently exhibited memory deficits and cognitive impairments that were remarkably analogous to those observed in older, non-modified animals.
Furthermore, when the research team intervened to reduce TNAP levels in a cohort of 2-year-old mice—an age equivalent to approximately 70 human years—they observed a significant restoration of the blood-brain barrier’s impermeability. This enhancement in barrier function was accompanied by a notable reduction in neuroinflammation. Crucially, these physiological improvements translated into enhanced performance on memory-based assessments for the treated mice.
"We were able to access and manipulate this biological mechanism even at a relatively late stage of life for the mice, and it proved to be remarkably effective," commented Gregor Bieri, PhD, a postdoctoral scholar within Dr. Villeda’s laboratory and a co-first author of the study.
The implications of these findings are far-reaching, particularly in the context of Alzheimer’s disease and the broader spectrum of brain aging. The research strongly suggests that the development of pharmaceutical agents designed to cleave proteins such as TNAP could represent a novel therapeutic strategy for the restoration of blood-brain barrier function, even in instances where it has already been compromised by the aging process.
"We are currently uncovering fundamental biological insights that have been largely overlooked by conventional Alzheimer’s research," Dr. Villeda articulated. "This work holds the potential to unlock entirely new avenues for therapeutic intervention, moving beyond the established strategies that predominantly focus their efforts exclusively on the brain itself."
The collaborative research effort involved numerous scientists from UCSF, including Karishma Pratt, PhD; Yasuhiro Fuseya, MD, PhD; Turan Aghayev, MD; Juliana Sucharov; Alana Horowitz, PhD; Amber Philp, PhD; Karla Fonseca-Valencia, degree; Rebecca Chu; Mason Phan; Laura Remesal, PhD; Andrew Yang, PhD; and Kaitlin Casaletto, PhD. A comprehensive list of all contributing authors can be found within the published paper.
The study received substantial financial support from a variety of esteemed institutions, including grants from the National Institutes of Health (specifically awards AG081038, AG086042, AG082414, AG077770, AG067740, and P30 DK063720), the Simons Foundation, the Bakar Family Foundation, the Cure Alzheimer’s Fund, the Hillblom Foundation, the Glenn Foundation, the Japan Society for the Promotion of Science (JSPS), a Japanese Biochemistry Postdoctoral Fellowship, the Multiple Sclerosis Foundation, Frontiers in Medical Research, the American Federation for Aging Research, the National Science Foundation, the Bakar Aging Research Institute, and the philanthropic contributions of Marc and Lynne Benioff.
About the Author
